Related Experiment Video
Updated: Jun 28, 2026
08:19
Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
Published on: November 17, 2015
17.9K
Engineered Liposomes in Interventional Theranostics of Solid Tumors
Nagavendra Kommineni1, Ruchita Chaudhari2, João Conde3
1Center for Biomedical Research, Population Council, New York, New York 10065, United States.
ACS Biomaterials Science & Engineering
|July 14, 2023
Summary
Engineered liposomal nanoparticles show promise for cancer theranostics, enabling targeted delivery of therapies and imaging agents. Surface modifications improve tumor selectivity and therapeutic efficacy, addressing key challenges for clinical translation.
Area of Science:
- Nanotechnology and Biomedical Engineering
- Oncology and Pharmaceutical Sciences
Background:
- Liposomal nanoparticles are advanced drug delivery systems with proven efficacy in cancer care.
- Liposomal theranostics integrate diagnostic and therapeutic agents for enhanced cancer treatment.
- Market-approved liposomal systems highlight their clinical relevance.
Purpose of the Study:
- To review the significance and challenges of liposomal nanoparticles in targeted cancer theranostics.
- To provide an overview of preclinical and clinical advancements in liposomal cancer therapy.
- To discuss the translational aspects of liposomal theranostics for solid tumors.
Main Methods:
- Review of existing literature on liposomal nanoparticles in cancer theranostics.
- Analysis of engineering approaches to enhance liposome performance.
- Evaluation of preclinical and clinical progress and translational challenges.
Main Results:
- Engineered liposomes demonstrate improved tumor selectivity and therapeutic activity.
- Surface modifications can overcome limitations like cargo leakage and poor targeting.
- Several liposomal hybrid systems have gained FDA approval and market access.
Conclusions:
- Liposomal theranostics offer a promising platform for targeted cancer treatment, combining imaging and therapy.
- Overcoming challenges in stability, targeting, and cargo retention is crucial for widespread clinical adoption.
- Continued research and engineering advancements are vital for realizing the full potential of liposomal medicines in oncology.
